iiinova — where your digital self keeps evolving

Reposted by Anna Brown

Max Gelman @maxgelman.bsky.social · 15/04/2025

Johnson & Johnson CEO Joaquin Duato subtly but assertively criticized President Donald Trump's plans for pharmaceutical tariffs, saying tax policy is a better way to onshore US drug manufacturing. endpts.com/jj-ceo-chide...

endpts.com

J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.

013

Anna Brown @annajbrown.bsky.social · 16/04/2025

Pharma tariffs are likely to leave little room to hide for companies as the 232 investigation hits all the major parts of the supply chain: endpts.com/trumps-pharm...

endpts.com

Pharma tariffs could leave little room to hide with sweeping probe underway

A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

020

Anna Brown @annajbrown.bsky.social · 11/04/2025

Yesterday I wrote a piece for @endpts.com on what Trump's potential tariff rollout could look like for pharmaceuticals: endpts.com/pharma-tarif... But CDMOs seem more concerned with the current FDA staff cutbacks delaying inspections: endpts.com/cdmos-antici...

endpts.com

Pharma tariffs: Here’s what a potential rollout could look like

Trump signals imminent pharma tariffs, with experts including Mollie Sitkowski of Faegre Drinker suggesting 25% levy possible. China's API exports to US could face major impact.

030

Reposted by Anna Brown

Liz Essley Whyte @lizessleywhyte.bsky.social · 01/04/2025

Former FDA Commissioner:

271037372

Reposted by Anna Brown

Endpoints News @endpts.com · 01/04/2025

🚨 Breaking: Firings swept across the FDA, gutting leadership and whole offices, as some staff found out their jobs were cut when they showed up to work on Tuesday. endpts.com/firings-swee...

endpts.com

Breaking: Firings sweep across FDA, gutting leadership and whole offices

Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal health agencies being implemented by the Trump administration.

222

Reposted by Anna Brown

Zachary Brennan @zacharybrennan.bsky.social · 26/02/2025

We are too! DM me or find me on Signal at zacharybrennan.20

01611

Reposted by Anna Brown

Zachary Brennan @zacharybrennan.bsky.social · 24/02/2025

Some of the user fee-funded staff at FDA were reinstated on Monday, after being laid off about a week ago for dubious reasons. 183 of the 230 staffers initially let go were supported by the user fee program endpts.com/some-fda-med...

endpts.com

Some FDA medical device staff reinstated just days after receiving pink slips

Some of the more than 200 staffers laid off at the FDA's Center for Devices and Radiological Health (CDRH) returned to work Monday, about a week after hearing their roles would be cut, several device ...

045

Reposted by Anna Brown

Sheryl Gay Stolberg @sherylnyt.bsky.social · 18/02/2025

Young scientists, doctors, and public health professionals who earned prestigious federal fellowships are getting the axe from Trump. Is this how to plan for the next pandemic? “We owe them a debt of gratitude, not a pink slip,” former agency heads said. www.nytimes.com/2025/02/18/u...

nytimes.com

Trump Cuts Target Next Generation of Scientists and Public Health Leaders

A core group of so-called disease detectives, who track outbreaks, was apparently spared. But other young researchers are out of jobs.

516865

Reposted by Anna Brown

Andrew Dunn @andrewedunn.bsky.social · 19/02/2025

Pfizer CEO Bourla: “Do I think we can convince them to do something bold in vaccines with Kennedy in HHS? Probably not. But do I think that we can convince them to do something very bold for cancer or for cardiovascular diseases with Kennedy in HHS? Absolutely I do.” endpts.com/pfizer-ceo-s...

endpts.com

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Over 500 pharma executives, lobbyists, consultants and other industry members gathered a couple miles from the White House on Tuesday, as top industry leaders took the stage and tried out some new mes...

012

Reposted by Anna Brown

Chris Geidner @chrisgeidner.bsky.social · 19/02/2025

BREAKING: Nonprofits sue over Trump's anti-diversity, anti-trans executive orders, alleging they violate the First Amendment & equal protection guarantees, are void for vagueness, exceed the president's authority, & violate the Administrative Procedure Act. storage.courtlistener.com/recap/gov.us...

The terms of the Executive Orders are extraordinarily vague and could prohibit
Plaintiffs from engaging in any targeted effort to help a specific group of people facing unfair disadvantages. The Executive Orders equate banned "DEIA" with any equity-related work— potentially including work that is specifically authorized or required by civil rights laws-and explicitly prohibit references to "DEI and DEIA principles, under whatever name they may appear." Without any discernible standards or criteria of what is and what is not "dangerous, demeaning," "immoral," and "illegal" DEIA,' as understood by this Administration, the future of Plaintiffs' fiscal viability and programming are subject to the unfettered discretion of an
Administration that has made clear its predisposition against any speech or action that advances equal opportunity for historically marginalized groups, including people of color, women, LGBTQ people, and/or people with disabilities. Such vague terms without sufficient standards or criteria
deprive Plaintiffs of their due process rights under the Fifth Amendment.
9. In addition to violating Plaintiffs' free speech and due process rights, the Executive
Orders have a clear discriminatory purpose in violation of equal protection: to malign the targeted communities; to undermine and dismantle a wide spectrum of policies, programs, and activities intended to help historically marginalized, underserved, and under-resourced groups; and to erase
transgender people from public life.

REQUEST FOR RELIEF
Plaintiffs respectfully request that the Court grant the following relief:
A.
A declaration pursuant to 28 U.S.C. § 2201 that Executive Order Nos. 14151,
14168, and 14173 and any implementing agency actions are unlawful, unconstitutional, and
invalid.
A permanent injunction enjoining Defendants, their officials, agents, employees,
assigns, and all persons acting in concert or participating with them from implementing or enforcing Executive Order Nos. 14151, 14168, and 14173, including without limitation the promulgation of any rules or regulations, in any manner against Plaintiffs by way of contract,
subcontract, purchase order, grant, or sub-grant.
C. A permanent injunction mandating that Defendants permanently rescind all agency-wide directives implementing and effectuating Executive Order Nos. 14151, 14168, and 14173 against Plaintiffs that were issued prior to this injunction.
D. A permanent injunction mandating that Defendants unwind, rescind, strike, modify, or otherwise rectify contracts, subcontracts, agreements, and/or any other such binding documents
entered into with Plaintiffs, in which terms, clauses, or provisions have been inserted pursuant to
or in furtherance of Executive Order Nos. 14151, 14168, and 14173.

193409957

Anna Brown @annajbrown.bsky.social · 19/02/2025

Hello! Still in the process of moving over to Bluesky, for new friends: I write about biomanufacturing and supply chains over at @endpts.com -- feel free to reach out at abrown@endpointsnews.com for tips or just to say hi! A taster of some manufacturing news today: endpts.com/pfizers-manu...

endpts.com

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has

110

Reposted by Anna Brown

George Conway ⚖️🇺🇸 @gtconway.bsky.social · 19/02/2025

We’ve seen this movie before.

543165313075

Reposted by Anna Brown

Endpoints News @endpts.com · 19/02/2025

Pfizer’s contract manufacturing arm operates 12 facilities in Europe. CEO Albert Bourla warned that the business could be vulnerable to tariffs on European imports proposed during Donald Trump’s presidency.

endpts.com

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe as the big pharma has

122